Latin America

Many have been the dead product of the disease of rabies, evil which has always manifested itself and that its scope and implications are very negative, which obliges not to neglect the respect, be very attentive with animals, even of the mascostas, as some dogs contact. Not surprising therefore, that comment, that this disease, if it is not treated with the utmost urgency, just causing the death of the patient. When a person is infected, the symptoms of the disease may take between 60 and 300 days to manifest itself is known, the world Organization of the health (who) handles data that corroborate that in some regions is still a major public health problem in some countries of Asia and Africa, which causes more than 55,000 deaths a yearof which the majority of the victims are minors 15 years of age. It is estimated that rabies kills 31,000 a year in Asia, which represents 60% of deaths from this cause in the world in recent years, the number of cases has increased in China and in Viet Nam due to the usual consumption for human consumption, without the proper conditions levels of dogs and cats. According to the latest statistics of the year 2007, in China, where less than 10% of dogs are vaccinated, 3380 people died from rabies Excel geosalud.com/enfermedades_infecciosas/rabia.htm, that the greatest risk of contracting rabies found in Africa, Asia and Latin America, either by wild animals (foxes, cats, mongooses, bats, monkeys, jackals, wolves, etc.), or more frequently by stray dogs.

The Asian continent has the largest number of cases of rabies in humans, since it represents more than 95% of all cases worldwide, and about 35,000 deaths per year. In 1983, who reported that rabies caused 50,000 deaths a year in countries where the disease is endemic, particularly Asia and the Indian subcontinent. Although it affects all ages, rabies is observed more often in children younger than 15 years, with some 40 cases produced in children aged 5-14 years of age.

Tags:
Category:

Medpace Inc Continues

CINCINNATI, OH (Marketwire January 18, 2010) Medpace, comprehensive clinical research, private property and global entity is pleased to announce that it has acquired Medical Consulting Dr. Schlichtiger GmbH, a research organization (CRO) European clinic with extensive experience in drug development that offers personalized on regulatory and pharmacological monitoring to pharmaceutical and biotechnology companies and nutritional services of all sizes, headquartered in Munich, Germany. Medical Consulting join his strategic experience Medpace in the sense of providing a centralized platform in Europe with respect to the presentation and approval by regulatory agencies as well as for managing and reporting on security. Medical Consulting is headed by Dr. in medicine Ursula Schlichtiger, Director General, and professional research with extensive experience in clinical development, regulatory and pharmacological monitoring Affairs.

Medical Consulting has been working throughout Europe since 1989. I welcome the incorporation of the DRA. Schlichtiger the team of Medpace to support our growing presence in the market development of medicines in Europe as General Manager and Senior Director of medical topics and regulation for Europe, said Dr. August Troendle, President Ejecutivo de Medpace. Dr. Schlichtiger is known in Europe as the professional of first-level Medical Consulting which he founded in 1989 and which led the company to be an organization with great appreciation by interact successfully with European State agencies. The integration of Medical Consulting Dr. Schlichtiger GmbH will begin immediately, with the intention of having it completed by mid-2010.

Medical Consulting executives will continue in their posts during the process of integration for the great benefit of our customers. ABOUT MEDPACE Medpace is a leading entity of complete clinical research that provides fundamental development in phases I to IV in programs of development of drugs and biological products and their corresponding devices. She has medical and regulatory experience in multiple therapeutic specialties, having met Medpace teams with more experience and more focused on the therapeutic activity of this industrial sector that carry out operations of the company at all levels, offering complete and services without discontinuity for drug development. In June 2009, Medpace received the nomination for best CRO of U.S. Investigators in the 2009 survey CenterWatch Site Survey. Medpace creates strategic partnerships with companies pharmaceutical and biotechnology in order to offer the most effective channels and best cost for the development of drugs, from the planning of programmes and their implementation until the approval of the products. With more than 900 employees and experience in clinical trials in more than 40 countries, Medpace has a range and a global capability allowing it to develop studies and meet the demands of the Regulation around the world. In addition to developing services in phases II to IV, Medpace offers clinical services in phase I / IIA Medpace Clinical Pharmacology, and specialized therapeutic trials and the central laboratories of Medpace Reference Laboratories, services of complete bioanalysis in all stages of the development of drugs Medpace Bioanalytical Laboratories, management and reading images of Imagepace. Please, visit on MEDICAL CONSULTING DR. Medpace website SCHLICHTIGER GmbH founded in 1989, Medical Consulting GmbH operates as a corporation with headquarters in Munich, Germany. Medical Consulting offers a full range of services for the record corresponding to the development of drugs, both at the level of Germany and throughout the European Union. The extensive experience of Medical Consulting in all aspects of clinical research and drug registration I has prepared to meet the regulatory requirements of the international authorities with regard to quality (CMC), to the preclinical and clinical studies.

Tags:
Category: